Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Medically reviewed by Suzanne Fisher, RDHypoglycemia (low blood sugar) treatments will depend on the severity of symptoms and ...

Amneal also reported it has received FDA approval for exenatide – a generic injectable glucagon-like peptide-1 receptor ...

As of March 24, 2025, both the FDA and the American Society of Health-System Pharmacists (ASHP) websites have listed branded ...

Each pen is for single use only ... American Diabetes Association (ADA) guidelines recommend using a glucagon-like peptide-1 (GLP-1) receptor agonist, such as Ozempic or Trulicity, in adults ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

In the US, Baqsimi is now competing head-to-head with Xeris’ Gvoke, pre-filled syringe and pen injector formulations of glucagon that don’t require the mixing steps and can be used in patients ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...